KUDU

Kudu Therapeutics is a San Diego-based biotechnology company focused on developing next-generation precision medicines for autoimmune and inflammatory diseases. The company was founded by a veteran leadership team, including former executives from Receptos and Gossamer Bio, with significant experience in immunology and drug development. Kudu's primary focus is on the selective modulation of the immune system, specifically targeting the P2X7 receptor pathway to treat chronic inflammatory conditions. By leveraging its deep expertise in small molecule discovery and precision immunology, Kudu aims to deliver therapies with superior efficacy and safety profiles. The company is backed by leading venture capital firms, including Westlake Village BioPartners and ARCH Venture Partners.